Gline Matthew bought ROIV
December 15, 2025 · Form 4 insider transaction
Gline Matthew bought 2,272,852 shares of Roivant Sciences Ltd. at $12.68 per share, a transaction worth $28.82M. The trade was recorded as option exercise and disclosed on an SEC Form 4, filed 2 days after the transaction.
Direction
Acquired (buy-side)
Shares
2,272,852
Price
$12.68
Total value
$28.82M
InsiderGline Matthew
RoleOfficer, Director
CompanyRoivant Sciences Ltd. (ROIV)
SecurityCommon Shares
Transaction codeM: Option exercise
Transaction dateDecember 15, 2025
Filing dateDecember 17, 2025
Shares owned after19,559,933
OwnershipDirect
10b5-1 planNo
AmendedNo